The clinical-stage generative AI drug discovery company recorded a net profit of $35.54 million and an adjusted net profit of $51.23 million, with positive operating cash flow, in its first interim report since listing on the Hong Kong Stock Exchange at the end of 2025.
The results, released August 26, 2026, mark the first time an AI-driven drug discovery company of Insilico’s profile has reported full-period profitability. The figure worth scrutinizing is not the margin but the revenue mix behind it.
Where the $106.3 Million Actually Came From
Nearly all of it came from dealmaking, not from selling software or an approved product. Revenue from drug discovery and pipeline development reached $103.1 million in the first half of 2026, up more than 300% year over year, driven by large upfront payments from business development deals signed during the period plus milestone payments from existing collaborations. Software solutions revenue was $2.70 million.
That composition matters for how the headline number should be read. Upfront and milestone payments are real cash and signal that large pharmaceutical companies will pay for Insilico’s platform and pipeline assets, but they are episodic rather than recurring, and they depend on a continuing pace of new deals. The total contract value of transactions the company announced in 2026 reached approximately $7.3 billion as of its latest practicable date.
The largest of those deals frame the commercial thesis. In June 2026 it announced a $2.5 billion AI drug discovery collaboration with SK Biopharmaceuticals, and in July 2026 a strategic collaboration with Takeda Pharmaceutical totaling approximately $600 million, including roughly $60 million in project initiation fees, near-term payments and milestones.
These are “up to” figures, which is the standard caution for this beat: the headline value of a biopharma collaboration is the ceiling if every milestone is hit, not the amount that changes hands. The cash that actually arrived in the period is what produced the $106.3 million.
The Pipeline the Deals Are Paying For
The commercial agreements rest on a pipeline the company says advanced on two fronts in the period. The most clinically advanced asset is rentosertib (ISM001-055), which the company says has initiated a large-scale Phase III trial in China for idiopathic pulmonary fibrosis. A nebulized inhalation formulation of the same asset received IND clearance from China’s Center for Drug Evaluation in April 2026.
Rentosertib is the program Insilico has longest pointed to as proof that a generative AI-discovered target and molecule can reach patients. Unite.AI covered its earlier Phase IIa results in pulmonary fibrosis, and the move into Phase III is the step that determines whether the platform’s efficiency claims survive contact with a registration-grade endpoint. That is a higher bar than the deal announcements, and it is the one to watch.
Other clinical movement in the period included the brain-penetrant NLRP3 inhibitor ISM8969/HT-001, co-developed with Hygtia Therapeutics, which received US FDA IND approval in January 2026 and completed first-in-human dosing in a Phase I trial in June 2026; and the pan-TEAD inhibitor ISM6331, which received Fast Track Designation from the US FDA in July 2026.
The Software Business Is the Part to Watch
The company is framing its MMAI Gym model training and evaluation ecosystem as a second revenue engine beyond dealmaking. In March 2026 it reached its first MMAI Gym-based AI model co-development collaboration with Liquid AI, delivering a lightweight on-premise scientific foundation model that the company says achieves cloud-model performance of tens of billions of parameters using only 2.6 billion parameters.
The ambition here is a durable, recurring software business rather than a dependence on episodic licensing events. At $2.70 million against $103.1 million in deal revenue, that engine is early. Whether it grows into a genuinely recurring line, and whether the preclinical pipeline converts into later-stage clinical readouts, will determine if the profitable half is a repeatable model or a strong dealmaking quarter annualized.
